US Patent 12,233,067: Ruxolitinib Vitiligo Claims, Scope, Exclusivity and Generic-Entry Risk

US Patent 12,233,067 protects a targeted treatment protocol for nonsegmental vitiligo using approximately 1.5% topical ruxolitinib, administered twice daily, in patients with defined depigmented-skin burdens and a specified clinical response. The patent is a method-of-treatment patent. It does not, based on the supplied claims, broadly claim ruxolitinib, ruxolitinib phosphate, or every topical ruxolitinib formulation.

The commercial importance of the patent depends on four elements: whether the relevant ruxolitinib product is covered by an Orange Book-listed use code, whether the claims are valid and enforceable, whether a generic applicant relies on the vitiligo indication, and whether the claimed T-VASI response can be established in an infringement proceeding.

What does US Patent 12,233,067 claim?

The independent claim requires all of the following:

Required element	Claim limitation
Disease	Nonsegmental vitiligo
Drug	Approximately 1.5% w/w ruxolitinib, calculated on a free-base basis
Route	Topical administration to a depigmented skin area
Frequency	Twice daily
Facial disease burden	At least 0.5% BSA
Non-facial disease burden	At least 3% BSA
Total disease burden	No more than 10% total BSA
Outcome	At least 75% improvement in total-body Vitiligo Area Scoring Index, or T-VASI75

The claim is cumulative. A competing product or treatment protocol must satisfy every limitation to fall within claim 1. A patient with more than 10% total BSA, a patient with less than the specified facial or non-facial burden, or a regimen administered once daily would not satisfy the literal wording of claim 1.

The patent does not appear to require that the composition be sold under the Opzelura brand. Infringement could potentially occur through use of any materially equivalent topical ruxolitinib composition that satisfies the concentration, dosing, disease, patient-selection and outcome limitations.

How broad is the scope of claim 1?

Claim 1 is narrower than a conventional composition claim but broader than a claim limited to a particular commercial package or brand.

Drug concentration

The phrase “about 1.5% w/w ruxolitinib ... on a free base basis” creates two issues.

First, the claim measures active-ingredient concentration by ruxolitinib free-base equivalent rather than by the mass of a salt. A formulation containing ruxolitinib phosphate must be converted to its ruxolitinib free-base equivalent for claim analysis.

Second, “about” introduces a range rather than an exact 1.500% concentration. The permissible range would ordinarily be determined through intrinsic evidence, prosecution history, specification data and expert testimony. A formulation containing 1.5% ruxolitinib phosphate by total salt weight is not automatically equivalent to a formulation containing 1.5% ruxolitinib free base.

Twice-daily administration

The twice-daily limitation narrows the claim materially. A once-daily product, intermittent regimen or physician-directed off-label regimen would present a stronger noninfringement position, although inducement theories could still depend on labeling, promotional conduct and physician-use evidence.

Patient-selection limitations

The claim targets patients with:

at least 0.5% facial BSA involvement;
at least 3% non-facial BSA involvement; and
no more than 10% total BSA involvement.

These limitations align the patent with a defined moderate disease population rather than all vitiligo patients. The total-body ceiling is particularly important. Treatment of a patient with 12% total BSA would fall outside the literal scope of claim 1 even if the patient otherwise has nonsegmental vitiligo and receives 1.5% ruxolitinib twice daily.

Clinical-outcome limitation

The requirement that the patient “achieves” T-VASI75 is an outcome limitation. It creates a potential enforcement burden because the patentee would need to show that the claimed regimen produced, or is intended to produce, the specified result in the accused treatment population.

For direct infringement, the claim does not merely require administration. It requires the claimed clinical response. Evidence could include clinical assessments, trial records, patient charts, investigator evaluations, photographs and validated T-VASI scoring.

What do claims 2 through 15 add?

Claims	Additional limitation	Commercial or legal effect
2	No laser or phototherapy	Excludes combination treatment involving those modalities
3	Ruxolitinib phosphate	Narrows the active ingredient to the phosphate salt
4-5	At least 24 weeks; T-VASI75 at week 24	Adds duration and a defined assessment point
6-7	At least 52 weeks; T-VASI75 at week 52	Extends the claimed treatment period
8	Clinically diagnosed vitiligo	Adds a diagnostic requirement
9	Patient aged 12 years or older	Aligns with the approved adolescent and adult population
10	Oil-in-water emulsion cream	Narrows the dosage form
11-14	Facial VASI75 or VASI90 at weeks 24 or 52	Adds facial-response endpoints and treatment-continuation conditions
15	Administration to a patient population	Potentially extends the claim from an individual patient to treatment of a defined group

Claims 4 through 7 are especially relevant to clinical-use labeling. A label that recommends ongoing twice-daily treatment for 24 or 52 weeks could create a stronger infringement theory than a label that does not specify those durations.

Claim 10 is narrower than claim 1 because it requires an oil-in-water cream. A nonaqueous ointment, gel, foam or other delivery system may avoid claim 10 while remaining potentially exposed to claim 1.

Claims 11 through 14 focus on facial response. A product that produces a high facial VASI response but does not satisfy T-VASI75 may still implicate those claims if the other limitations are met.

What formulations are protected by US 12,233,067?

The supplied claims protect use of a topical formulation containing approximately 1.5% free-base-equivalent ruxolitinib. Claim 10 specifically covers an oil-in-water emulsion that is a cream.

The claims do not, on their face, require particular excipients, preservatives, penetration enhancers, particle sizes, manufacturing steps or packaging configurations. That distinguishes this patent from a formulation patent directed to a specific vehicle or excipient system.

The most exposed product profile is:

Product characteristic	Exposure under the supplied claims
1.5% topical ruxolitinib cream	High, if other claim elements are met
Ruxolitinib phosphate cream	High under claim 3 and potentially claim 1
Twice-daily use	Required by claim 1
Treatment of nonsegmental vitiligo	Required by claim 1
Treatment of patients aged 12 or older	Covered by claim 9
Treatment of disease over 10% total BSA	Outside literal claim 1
Once-daily treatment	Outside literal claim 1
Phototherapy combination	Potentially outside claim 2, but not necessarily outside claim 1
Non-cream formulation	Potentially outside claim 10, but not necessarily outside claim 1
Atopic dermatitis treatment	Not covered by the supplied claims

How does the patent compare with the underlying ruxolitinib patent estate?

US 12,233,067 should be analyzed as one layer of the ruxolitinib estate rather than as the foundational chemical patent.

Patent category	Typical protection	Relevance to Opzelura and generic entry
Compound patents	Ruxolitinib molecule and salts	Broad chemical protection, generally older and closer to expiration
Formulation patents	Cream vehicle, excipients and physical properties	Can block or complicate formulation substitution
Method-of-use patents	Atopic dermatitis, vitiligo and other inflammatory diseases	Can support Orange Book use-code protection
Dosing patents	Concentration, frequency, treatment duration	Relevant to label-based infringement
Patient-selection patents	Disease severity, age, BSA and response criteria	Narrower but potentially difficult to design around
Manufacturing patents	Synthesis, purification and scale-up	May affect supply but does not necessarily block a noninfringing formulation

US 12,233,067 is most significant as a patient-selection and clinical-outcome patent. Its commercial force is narrower than a patent covering the active ingredient or the entire topical formulation, but it can delay a full-label generic strategy if the claimed vitiligo population is commercially important.

When does ruxolitinib lose regulatory exclusivity?

Ruxolitinib’s regulatory exclusivity must be separated from patent protection.

Opzelura was approved by FDA in September 2021 for topical treatment of mild-to-moderate atopic dermatitis in certain patients. FDA later approved it in July 2022 for topical treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older with affected body surface area within the labeled limit. The vitiligo approval was based on the TRuE-V clinical program and related evidence submitted to FDA. [1][2]

Regulatory exclusivity does not automatically track the life of US 12,233,067. A three-year exclusivity period may attach to an approval supported by new clinical investigations, but that exclusivity does not prevent all ANDA activity. It generally restricts approval of a competing application relying on the protected new clinical investigations for the same condition or use during the applicable period. Patent protection can continue after regulatory exclusivity ends. [3]

The principal regulatory pathways are:

an ANDA referencing the approved ruxolitinib product;
a Paragraph IV certification against listed patents;
a section viii statement omitting a patented method of use; or
a 505(b)(2) application for a modified formulation, concentration, route or indication.

What is the Orange Book status of US 12,233,067?

A patent number is not, by itself, proof that FDA has listed the patent in the Orange Book. The controlling records are FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and the patent and exclusivity information submitted by the NDA holder. [4]

If US 12,233,067 is listed against the relevant Opzelura NDA with a vitiligo use code, an ANDA applicant seeking a label that includes the patented use could face a Paragraph IV certification. If the applicant removes the vitiligo indication under section viii, the patent may still matter commercially if the proposed labeling, promotional materials or foreseeable physician use encourage the patented regimen.

A method-of-use listing is generally more vulnerable to a label carve-out than a formulation or active-ingredient patent. The practical effect depends on the precision of the use code and whether the patented method can be removed without making the generic product commercially unattractive.

Which companies are challenging the ruxolitinib patent estate?

The supplied information does not identify a specific Paragraph IV filer, litigation defendant or settlement agreement involving US 12,233,067. Patent Center, FDA’s Orange Book records and federal court dockets are the controlling sources for any company-specific challenge. [4][5]

No biosimilar pathway applies to ruxolitinib. Ruxolitinib is a small-molecule active ingredient. Competition would generally proceed through an ANDA or, in some cases, a 505(b)(2) application. Calling a future ruxolitinib product a biosimilar would be legally incorrect.

What generic entry risks exist?

Full-label generic

A full-label ANDA carrying nonsegmental vitiligo treatment directions would face the greatest exposure. The generic label could reproduce the 1.5% concentration, twice-daily administration, age range, disease population and treatment outcomes associated with the patented method.

A Paragraph IV challenge could trigger patent litigation under the Hatch-Waxman Act. A timely suit by the NDA holder or patent owner can impose a statutory approval stay of up to 30 months, subject to statutory exceptions and court action. [3]

Section viii carve-out

A generic applicant could attempt to omit the vitiligo indication and seek approval for another approved use, such as atopic dermatitis. This approach would reduce direct label exposure but would not eliminate risk if the remaining label or promotional conduct encourages the patented vitiligo regimen.

Formulation substitution

A different vehicle could avoid claim 10, but it would not necessarily avoid claim 1. The broadest supplied claim is tied to active concentration, administration, patient population and clinical response rather than to a particular cream architecture.

Dose or regimen design-around

A once-daily regimen, a different concentration or treatment of patients outside the claimed BSA range could avoid literal infringement. The commercial problem is that such a regimen may not be substitutable for the FDA-approved product without separate clinical and regulatory support.

How strong is the patent estate for nonsegmental vitiligo?

The patent has meaningful commercial value but a narrower enforcement profile than a compound or formulation patent.

Strength factor	Assessment
Disease specificity	Strong; focused on nonsegmental vitiligo
Concentration specificity	Strong; approximately 1.5% free-base-equivalent ruxolitinib
Dosing limitation	Strong; twice daily
Patient selection	Narrow and potentially design-aroundable
Clinical endpoint	Useful for linking use to clinical evidence, but creates proof issues
Formulation coverage	Moderate; claim 10 covers oil-in-water cream
Age coverage	Commercially aligned with the approved 12-plus population
Biosimilar relevance	None
Generic label vulnerability	Meaningful, especially for a full-label ANDA
Direct patient-use enforcement	Fact intensive because of the outcome requirement

The strongest commercial position would arise if the patent is listed with a precise vitiligo use code, the product’s principal commercial market is the claimed patient population, and the label expressly recommends the claimed concentration and twice-daily regimen.

What patent litigation and settlement issues matter?

The key litigation questions are likely to include:

Whether “about 1.5%” has a sufficiently definite scope.
Whether the free-base calculation is satisfied by ruxolitinib phosphate.
Whether the BSA thresholds are measured at baseline, during treatment or at another specified time.
Whether T-VASI75 is a true claim limitation requiring proof of patient response.
Whether a generic label induces performance of the patented method.
Whether the claimed outcome is enabled across the full claimed patient population.
Whether the claims are anticipated or obvious based on the TRuE-V clinical program, earlier ruxolitinib studies or other JAK-inhibitor vitiligo evidence.
Whether the patient-population language in claim 15 is definite and adds a meaningful limitation.

The supplied claims do not identify a settlement, authorized generic arrangement, license or covenant not to sue. Any such agreement would require confirmation through the FTC pharmaceutical patent-settlement repository, SEC filings, FDA records or court filings. [6]

What are the patent expiration and geographic coverage implications?

US patent protection is territorial. US 12,233,067 does not itself block sales in Europe, Japan, Canada or other markets. Foreign rights must be reviewed family member by family member through the relevant national registers and the underlying priority chain.

For a US utility patent, the nominal term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers. The issue number alone does not establish the expiration date. The authoritative term data are the patent front page, USPTO Patent Center prosecution record and any terminal-disclaimer or PTA information. [5][7]

Key Takeaways

US 12,233,067 is a method-of-treatment patent focused on nonsegmental vitiligo.
Claim 1 requires approximately 1.5% free-base-equivalent ruxolitinib, topical twice-daily dosing, defined BSA thresholds and achievement of T-VASI75.
The patent does not broadly claim all ruxolitinib products or all vitiligo treatment.
Claim 10 specifically covers an oil-in-water cream, while claim 1 is not limited to a cream.
Claims 4 through 7 add 24-week and 52-week treatment milestones.
Claims 11 through 14 add facial VASI75 and VASI90 outcomes.
Ruxolitinib is a small molecule, so future competition would use an ANDA or 505(b)(2) pathway, not a biosimilar application.
A full-label generic would face greater exposure than a section viii carve-out or a noninfringing alternative regimen.
Orange Book listing, use-code wording, patent-term data and any Paragraph IV litigation are decisive commercial facts.
The principal validity risks concern definiteness, enablement, obviousness, claim construction and proof of the clinical-outcome limitation.

FAQs

Is US 12,233,067 a composition patent for Opzelura?

No. The supplied claims are method claims. They cover specified use of topical ruxolitinib in nonsegmental vitiligo rather than the composition in the abstract.

Does a different ruxolitinib cream automatically avoid the patent?

No. A different excipient system may avoid claim 10, but claim 1 is not limited to a particular cream vehicle. The alternative product would still need to avoid the concentration, dosing, disease, BSA and response limitations.

Can a generic launch for atopic dermatitis without a vitiligo indication?

Potentially. A section viii carve-out may remove the patented vitiligo use, but the remaining label and promotional conduct must not induce the claimed vitiligo treatment.

Does treatment with phototherapy avoid all claims?

No. Claim 2 excludes a method that includes laser or phototherapy, but claim 1 does not contain that exclusion. Phototherapy may therefore avoid claim 2 while remaining relevant to claim 1.

Does the patent cover patients younger than 12 years?

Claim 9 is limited to patients aged 12 years or older. Claim 1 itself does not include an age limitation, so the answer depends on whether the younger patient otherwise satisfies every limitation of claim 1 and whether the patent’s construction supports that application.

References

U.S. Food and Drug Administration. (2022). FDA approves first treatment for vitiligo. https://www.fda.gov
U.S. Food and Drug Administration. (2023). Opzelura prescribing information. Incyte Corporation. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Approved drug product patent and exclusivity information. https://www.accessdata.fda.gov
United States Patent and Trademark Office. (2025). Patent No. US 12,233,067 and Patent Center records. https://patents.uspto.gov
Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act. https://www.ftc.gov
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. https://www.uspto.gov

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, WHEREIN THE DEPIGMENTED AREA IS ≥ 0.5% BSA ON THE FACE, ≥ 3% BSA ON NON-FACIAL AREAS, AND NOT >10% BSA ON TOTAL BODY AREA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020290995	⤷ Start Trial
Australia	2026200410	⤷ Start Trial
Canada	3150975	⤷ Start Trial
Canada	3195357	⤷ Start Trial
China	116261447	⤷ Start Trial
European Patent Office	3982971	⤷ Start Trial
European Patent Office	4213800	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,233,067

Which drugs does patent 12,233,067 protect, and when does it expire?

Summary for Patent: 12,233,067